0001448431-26-000007
SEC filingOptimizeRx Corporation dismissed UHY LLP as its independent auditor on March 25, 2026, and appointed Grant Thornton LLP on March 26, 2026, with clean prior audit reports except for a previously disclosed material weakness.
The change in independent registered public accounting firm from UHY LLP to Grant Thornton LLP was approved by OptimizeRx's Audit Committee without any disagreements on accounting principles or financial disclosures during the audited periods. The prior material weakness, detailed in the 2025 10-K, pertains specifically to internal controls over third-party service organization data completeness and accuracy, but did not lead to restatements or impact audit opinions. UHY confirmed agreement with the company's Item 4.01 disclosures in Exhibit 16.1. This routine auditor transition, with no reported issues beyond the known control deficiency, suggests continuity in financial reporting integrity under the new firm for the 2026 fiscal year.